Preclinical imaging efforts in models of HER2-positive breast cancer found that the homogeneous 89Zr-pertuzumab exhibited excellent in vivo behavior with improved performance relative to that of the stochastically lysine (isothiocyanate) labeled variant at similar labeling density. This evidence concerns the gene ERBB2 and breast cancer.